Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
Muik A, Lui BG, Wallisch AK, Bacher M, Mühl J, Reinholz J, Ozhelvaci O, Beckmann N, Güimil Garcia RC, Poran A, Shpyro S, Finlayson A, Cai H, Yang Q, Swanson KA, Türeci Ö, Şahin U. · 2022
Read Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. by Muik A, Lui BG, Wallisch AK, Bacher M, Mühl J, Reinholz J, Ozhelvaci O, Beckmann N, Güimil Garcia RC, Poran A, Shpyro S, Finlayson A, Cai H, Yang Q, Swanson KA, Türeci Ö, Şahin U. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9836206.txt.
Introduction
Muik and co-authors test whether vaccine sera can neutralize the Omicron variant of SARS-CoV-2. Omicron carries an unseen load of spike mutations. Those changes threatened to blunt antibody recognition badly. The team used sera from people given the BNT162b2 vaccine.
Sera came from 51 participants after two or three doses. They faced Wuhan, Beta, Delta, and Omicron pseudoviruses in tests. After two doses, Omicron blocking fell more than 22-fold. Wuhan blocking titers stood far higher in the same sera. One month after a third dose, the picture flipped. Omicron titers rose 23-fold from the two dose level. They matched Wuhan titers seen after two doses. Live virus tests on a subset confirmed the pattern. The authors say three doses may protect against Omicron disease.
Catalog record
| CREATOR | Muik A, Lui BG, Wallisch AK, Bacher M, Mühl J, Reinholz J, Ozhelvaci O, Beckmann N, Güimil Garcia RC, Poran A, Shpyro S, Finlayson A, Cai H, Yang Q, Swanson KA, Türeci Ö, Şahin U. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera By Alexander Muik, Bonny Gaby Lui, Ann-Kathrin Wallisch, Maren Bacher, Julia Mühl, Jonas Reinholz, Orkun Ozhelvaci, Nina Beckmann, Ramón de la Caridad Güimil Garcia, Asaf Poran, Svetlana Shpyro, Andrew Finlayson Published in: Science (New York, N.y.) DOI: 10.1126/science.abn7591 ABSTRACT Abstract The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or Omicron pseudoviruses with sera of 51 participants who received two or three doses of the messenger RNA (mRNA)–based COVID-19 vaccine BNT162b2. After two doses, Omicron-neutralizing titers were reduced >22-fold compared with Wuhan-neutralizing titers. One month after the third vaccine dose, Omicron-neutralizing titers were increased 23-fold relative to their levels after two doses and were similar to levels of Wuhan-neutralizing titers after two doses. The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed with sera from a subset of participants using live SARS-CoV-2. These data suggest that three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19. Since the first reports of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans in December 2019, numerous genetically distinct lineages have evolved. Among those, variants of concern (VOCs), especially the Alpha (B.1.1.7) and Delta (B.1.617.2) variants, were associated with increased viral transmissibility and sparked new waves of infection, with Delta [first designated a VOC on 11 May 2021 (1)] quickly becoming a globally dominant variant (2). On 26 November 2021, a new VOC—Omicron (B.1.1.529)—was reported by the World Health Organization (WHO) (3). Omicron is a highly divergent variant and harbors a previously unseen number of mutations in its spike (S) glycoprotein (4). Fifteen mutations are located in the receptor binding domain and another eight mutated sites are found in the N-terminal domain, both being immunodominant targets of neutralizing antibodies elicited by COVID-19 vaccines or by SARS-CoV-2 infection (5, 6). Some amino acid changes [Δ69/70, T95I, G142D, Δ145, K417N, T478K, N501Y, and P681H (T, Thr; I, Ile; G, Gly; D, Asp; K, Lys; N, Asn; Y, Tyr; P, Pro; H, His)] are shared mutations also found in the Alpha, Beta (B.1.351), Gamma (P.1), or Delta VOCs and were described to lead to increased transmissibility, as well as to a typically mild partial escape from vaccine-induced humoral immunity (7–10). The BNT162b2 COVID-19 mRNA vaccine contains lipid nanoparticle–formulated mRNA that encodes the SARS-CoV-2 S glycoprotein from the parental Wuhan reference strain (Wuhan-Hu-1) (11). Administration of two 30-μg doses of BNT162b2 was shown to have 95% efficacy in a phase 3 trial (12) and to elicit strong antibody responses, effectively neutralizing the parental strain as well as diverse SARS-CoV-2 VOCs (13–15). Because neutralizing antibody titers are strongly predictive of the degree of immune protection against symptomatic SARS-CoV-2 infection (16), it is important to understand the effect of the new mutations in Omicron on recognition by neutralizing antibodies in convalescent and vaccinated individuals. To evaluate whether BNT162b2-elicited antibodies (11) are capable of neutralizing the Omicron variant, we used two orthogonal test systems: a pseudovirus-neutralization test (pVNT) that has been shown to be in close concordance with live SARS-CoV-2–neutralization assays (17, 18), as well as a live SARS-CoV-2–neutralization test (VNT). For the former, we generated vesicular stomatitis virus (VSV)–SARS-CoV-2-S pseudoviruses bearing the S proteins of the Wuhan strain, Omicron, Beta [as a benchmark for partially reduced neutralization (7) without major impact on effectiveness (19, 20)], or Delta (the predominant strain until mid-December 2021). BNT162b2 immune sera from vaccinated individuals between 20 and 72 years of age (with more than one-third being ≥56 years of age; table S1) were obtained from different clinical trials—the phase 1/2 trial BNT162-01 (NCT04380701), the phase 2 rollover trial BNT162-14 (NCT04949490) conducted in Germany, and the global phase 2 trial BNT162-17 (NCT05004181) (see materials and methods). Neutralizing titers against VSV-SARS-CoV-2-S pseudoviruses were analyzed with serum drawn from 32 participants from the BNT162-01 trial 21 days (median of 22 days; range: 19 to 23 days) after two doses of BNT162b2 (median time from dose one to dose two: 21 days; range: 19 to 23 days; table S1) and with serum drawn from 30 participants from the BNT162-14 (n = 11) and BNT162-17 (n = 19) trials 1 month (median: 28 days; range: 26 to 30 days) after the third dose of BNT162b2 (median time from dose two to dose three: 219 days; range: 180 to 342 days). Eleven of the individuals in this analysis were rolled over from the BNT162-01 into the BNT162-14 trial and were included in a longitudinal analysis of neutralizing antibody responses against Wuhan or Omicron variant pseudovirus. These individuals were immunized with a third dose of BNT162b2, with sera collected (i) 21 days after the second dose (median: 21 days; range: 19 to 23 days), (ii) directly before the third dose (median: 256 days after dose two; range: 180 to 342 days), and (iii) 1 month (28 days) after the third dose. After two doses of BNT162b2, geometric mean neutralization titers (GMTs) against Omicron pseudovirus were reduced 22.8-fold compared with those for the Wuhan reference pseudovirus (Fig. 1; GMT of 7 versus 160). Twenty of 32 immune serum specimens displayed no detectable neutralizing activity against Omicron (table S2). By contrast, the majority of sera neutralized Beta and Delta pseudoviruses with GMTs of 24 and 73, respectively. This corresponds to 6.7- and 2.2-fold reductions in neutralization activity compared with the Wuhan pseudovirus and is in line with previous reports (11, 14, 15, 21). [Figure: 50% pseudovirus-neutralization titers (pVNT50) of sera from vaccine recipients, collected after two or three doses of BNT162b2 against VSV-SARS-CoV-2-S pseudovirus bearing the Wuhan, Omicron, Beta, or Delta variant S protein.N = 32 serum specimens from participants in trial BNT162-01, drawn 21 days after dose two, and n = 30 serum specimens from participants in the BNT162-14 (n = 11) and BNT162-17 (n = 19) trials, drawn 1 month after dose three, were tested. Each specimen was tested in duplicate, and geometric mean 50% pseudovirus-neutralizing titers (GMTs) were plotted. Below the limit of detection (LOD), LOD/2 values were plotted. Group GMTs (values) and 95% confidence intervals are indicated.] One month after the third BNT162b2 dose, neutralizing GMTs against the Omicron variant pseudovirus increased 23.4-fold relative to their levels 21 days after the second dose (GMT of 164 versus 7) and were comparable to neutralizing GMTs against the reference Wuhan pseudovirus at 21 days after two doses of BNT162b2 (GMT of 164 versus 160). Twenty-nine of 30 serum specimens were capable of neutralizing the Omicron pseudovirus (table S3). The third dose of BNT162b2 also increased neutralizing activity against Beta, Delta, and Wuhan pseudoviruses, with GMTs of 279, 413, and 368, respectively. For 11 individuals included in the aforementioned analyses, a longitudinal analysis of neutralizing titers against Omicron and Wuhan pseudovirus was performed. Twenty-one days after dose two, sera exhibited a 21.4-fold reduction in GMT against the Omicron variant compared with the Wuhan reference pseudovirus (fig. S1; GMT of 7 versus 150). Before receiving the third dose of BNT162b2 (at a median 256 days after dose two), neutralizing titers against